Insulet (NASDAQ:PODD)‘s stock had its “buy” rating reissued by equities research analysts at Barclays in a report released on Wednesday. They presently have a $78.00 price objective on the medical instruments supplier’s stock. Barclays’ price target suggests a potential upside of 14.64% from the stock’s previous close.

A number of other equities research analysts have also weighed in on PODD. BidaskClub upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Canaccord Genuity reiterated a “hold” rating and issued a $50.00 price objective on shares of Insulet in a research report on Wednesday, September 27th. Robert W. Baird lifted their price objective on Insulet from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Wedbush reiterated a “buy” rating and issued a $65.00 price objective (up from $60.00) on shares of Insulet in a research report on Tuesday, October 10th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $74.00 price objective (up from $65.00) on shares of Insulet in a research report on Thursday, October 12th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Insulet has a consensus rating of “Buy” and an average price target of $61.29.

Insulet (NASDAQ PODD) traded down $2.03 on Wednesday, reaching $68.04. The company had a trading volume of 592,400 shares, compared to its average volume of 502,452. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet has a fifty-two week low of $36.80 and a fifty-two week high of $72.99.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company earned ($0.05) EPS. research analysts forecast that Insulet will post -0.42 earnings per share for the current fiscal year.

In other news, Director James C. Mullen bought 2,500 shares of the stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $67.45 per share, for a total transaction of $168,625.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.90% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in Insulet during the third quarter valued at $33,373,000. Janus Henderson Group PLC purchased a new position in Insulet during the second quarter valued at $27,428,000. JPMorgan Chase & Co. raised its stake in Insulet by 104.9% during the third quarter. JPMorgan Chase & Co. now owns 611,595 shares of the medical instruments supplier’s stock valued at $34,035,000 after buying an additional 313,093 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in Insulet by 29.6% during the second quarter. Lord Abbett & CO. LLC now owns 838,302 shares of the medical instruments supplier’s stock valued at $43,013,000 after buying an additional 191,217 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Insulet by 120.7% during the second quarter. Renaissance Technologies LLC now owns 328,200 shares of the medical instruments supplier’s stock valued at $16,840,000 after buying an additional 179,500 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/barclays-reiterates-buy-rating-for-insulet-podd/1766278.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.